ARTICLE | Management Tracks
Novartis veteran Fox to head Teva’s U.S. commercial business
Plus: Rich Scott succeeding Chris Wigley at Genomics England, and updates from Sonoma, PIC, Turbine and LCRF
September 29, 2023 11:43 PM UTC
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) hired Christine Fox to be the new head of Teva’s U.S. commercial business. Fox, who was global president, gene therapies at Novartis AG (SIX:NOVN; NYSE:NVS), succeeds EVP, North America Commercial Sven Dethlefs, who will leave Teva on Nov. 17.
Genomics England Ltd. CMO and Deputy CEO Rich Scott will become interim CEO on Oct. 31, succeeding Chris Wigley. Wigley, whose departure was first announced in May, recently joined The BioCentury Show to discuss Genomics England’s next steps, its plans to expand to other omics, and how it’s addressing near-term hurdles faced by the whole field. ...